FDA Panel Rejects Diabetes Drug Citing Cancer Risks

Cancer Risks SILVER SPRING, Md. — An FDA adivsory committee has voted 9-6 against recommending approval for the novel diabetes drug dapagliflozin. The panel

Leave a Reply

Your email address will not be published. Required fields are marked *